DACS
VKTX icon

Dymon Asia Capital (Singapore)’s Viking Therapeutics VKTX Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,000
Closed -$317K – 143
2024
Q3 		$317K Sell
5,000
-3,000
-38% -$176K 0.09% 84
2024
Q2 		$424K Buy
+8,000
New +$524K 0.11% 83

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s VKTX Position: Q4 2024 in Review

Dymon Asia Capital (Singapore) sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 5,000 shares — an estimated $317K sold.

Dymon Asia Capital (Singapore) first reported a position in VKTX in Q2 2024 and held it in 2 quarters. The position peaked at $424K in Q2 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • Dymon Asia Capital (Singapore) reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 5,000 Viking Therapeutics shares in Q4 2024, an estimated $317K.
  • Dymon Asia Capital (Singapore) first reported a position in Viking Therapeutics in Q2 2024 and held it in 2 quarters.
  • Dymon Asia Capital (Singapore)'s Viking Therapeutics position peaked at $424K in Q2 2024.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q4 2024, filed 13 Feb 2025.